Levocetirizine (R) -enantiazine Cetirizine is a potent and selective antagonist of peripheral histamine H-receptors1. It inhibits endothelial migration of eosinophils through skin and lung cells. The effect of a dose of levocetirizine equal to half the dose of cetirizine is comparable to that of Cetirizine, both on the skin and on the nasal mucosa. The drug relieves the symptoms of allergic rhinitis, including the feeling of nasal congestion. The drug is rapidly and extensively absorbed after oral administration. The maximum plasma concentration occurs after 0.9 h after administration. The degree of absorption depends on the dose and does not depend on food intake. It is 90% bound to plasma proteins. Levocetirizine is metabolised in less than 14%. T0,5 in adults it is 7.9 ± 1.9 h. Levocetirizine and its metabolites are mainly excreted in the urine - an average of 85.4% of the administered dose. Only 12.9% of the dose is excreted in the faeces.
Contraindications:
Hypersensitivity to levocetirizine, other piperazine derivatives or other components of the preparation. Severe renal impairment with creatinine clearance <10 ml / min. Galactose intolerance, Lapp lactase deficiency, malabsorption of glucose-galactose (due to the lactose content).
Precautions:
It is not recommended for use in infants and young children under the age of 2 years. Tabling is not recommended. powl. children aged 2-6, due to the inability to properly adjust the dose in this form; It is recommended to use levocetirizine preparations in forms intended for children. Caution is advised when taking the drug together with alcohol.
Pregnancy and lactation:
Caution should be exercised when prescribing to pregnant women and during breastfeeding.
Side effects:
Common: headache, drowsiness; dry mouth; fatigue. Uncommon: abdominal pain, weakness. Very rare: weight gain, abnormal liver function tests; hypersensitivity, including anaphylaxis; aggression, agitation; convulsions; blurred vision; palpitations; shortness of breath; nausea; hepatitis; angioneurotic edema, persistent drug eczema, pruritus, rash, urticaria; muscle aches.
Dosage:
Orally. Adults and children> 6 years: 5 mg once a day (1 table). Adult patients with impaired renal function: mild renal impairment (creatinine clearance 50-79 ml / min): 5 mg once daily; moderate renal impairment (creatinine clearance 30-49 ml / min): 5 mg (every 2 days, severe renal impairment (creatinine clearance <30 ml / min): 5 mg every 3 days. Contraindicated in patients with end-stage renal disease (creatinine clearance <10 ml / min - dialysis patients.) In children with renal impairment, the dose should be adjusted individually for the renal clearance and the body weight of the child Treatment of allergic rhinitis may be discontinued after symptoms have resolved and resumed if they recur. Tabulate whole, with liquid, regardless of the meal.
(C)
